Injectable drug delivery devices market to reach $79.51 billion by 2030

The injectable drug delivery devices market is projected to grow from $54.3 billion in 2025 to $58.69 billion in 2026, with North America still leading while Asia-Pacific is expected to grow fastest. The report points to chronic disease rates, biologics growth, and self-administration trends as the main forces reshaping demand.

Why it matters: - Injectable drug delivery devices are becoming more important as chronic disease rates rise and more treatment moves outside hospitals. - The market’s growth points to stronger demand for devices that support self-administration, dose accuracy, and patient safety. - Expanding use of biologics, biosimilars, and home healthcare services is reshaping how injectable therapies are delivered.

What happened: - The Business Research Company released its report, Injectable Drug Delivery Devices Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report estimates the market will grow from $54.3 billion in 2025 to $58.69 billion in 2026. - The report projects the market will reach $79.51 billion by 2030. - North America held the largest regional share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report includes coverage of South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - A free sample is available here. - The full report is available here.

The details: - Injectable drug delivery devices are medical instruments used to administer medication directly into the body by injection. - The devices support intravenous, subcutaneous, intradermal, intra-peritoneal, and intramuscular delivery. - The report cites chronic disease growth, biologics and biosimilars expansion, more hospital-administered injectable therapies, better sterile manufacturing, and wider access to injection devices as near-term growth drivers. - The forecast also points to a shift toward self-administration devices, personalized drug delivery, a larger biologic drug pipeline, more investment in smart injection technology, and broader home healthcare adoption. - Emerging product trends include prefilled syringes, safety syringes, autoinjectors, pen injectors, wearable infusion pumps, and implantable infusion pumps. - Dose accuracy and patient safety remain central design priorities across the category. - The UK’s National Health Service reported in June 2024 that 3,615,330 people registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022.

Between the lines: - The market is shifting from clinic-centered delivery toward devices that fit chronic care and at-home use. - The emphasis on smart and wearable systems suggests device makers are competing on convenience, safety, and adherence rather than basic delivery alone. - Faster growth in Asia-Pacific likely reflects broader access to care, rising disease burden, and expanding healthcare infrastructure.

What's next: - The market is expected to keep growing through 2030 as biologic therapies expand and more patients use injectable treatments at home. - Device development will likely continue to focus on safer, more precise, and easier-to-use formats. - The report also adds new analytics for 2026, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies, and future trend analysis. - The Business Research Company lists Saumya Sahay as an expert contact for the report.